In 2025, the GLP-1 revolution has fundamentally shifted from a weight-loss trend to a pillar of the medical aesthetics industry. As of late 2025, GLP-1 medications have surpassed professional-grade skin care in consumer spending at medical spas, trailing only behind neurotoxins and dermal fillers, according to finding from Guidepoint Qsight as shared in a summer 2025 Modern Aesthetics article.
GLP-1’s had quite a banner year in 2025, including the following milestones.
Key 2025 GLP-1 Product Milestones
• The Wegovy Pill Approval: In December 2025, the FDA approved the first oral GLP-1 specifically for weight loss (a 25mg semaglutide tablet). This has lowered the barrier for patients who don’t like needles, but still desire the aesthetic benefits of weight loss.
• First Generic GLP-1: The FDA approved the first generic version of Saxenda (liraglutide) from Teva Pharamceuticals in August 2025. This has introduced a more affordable entry point for patients, driving even more volume into medical spas.
• Expanded Indications: GLP-1s received major new FDA approvals in 2025 for sleep apnea (Zepbound) and liver disease/MASH (Wegovy), further medicalizing the wellness journey offered in aesthetic clinics.
The Rise of Ozempic Face and Body Treatments
Rapid weight loss has created a surge in secondary aesthetic concerns, leading to the development in 2025 of specific protocols to address these concerns.
• Biostimulator Boom: Treatments like Sculptra and Radiesse are now the No. 1 choice for Ozempic face. Since weight loss deflates facial fat pads, some injectors are moving away from traditional HA fillers toward biostimulators that rebuild the skin’s structural collagen.
• Combination Therapies: The gold standard in 2025 is combination therapy. Patients are rarely getting just one treatment; they are bundling GLP-1s with:
o Skin Tightening: Radiofrequency (RF) microneedling, such as VirtueRF, to treat skin laxity after fat loss.
o Muscle Sculpting: Devices like Emsculpt Neo are being used to combat GLP-1 muscle wasting.
• Topical Innovators: Brands like Image Skincare (Vol.U.Lift) launched specialized topical lines in 2025 designed specifically to plump skin and mimic the look of lost facial volume for those on weight-loss medications.
• Specialized Treatment Protocols: Following are examples of top-rated treatment protocols currently dominating U.S. aesthetic practices to address Ozempic Face.
- The Galderma SHAPE Up Protocol
This combination therapy for is supported by Phase IV clinical trial data released in July. It is designed for patients with diffuse volume loss and skin hollowing.
• Treatment Cycle: 3 sessions spaced 4–8 weeks apart.
• The Mix:
o Sculptra (PLLA): Injected globally to stimulate “bio-synthetic” collagen and thicken the dermis.
o Restylane Lyft or Contour: Placed strategically in the midface (cheeks) for immediate structural projection.
• Result: 91% patient recommendation rate, with results lasting up to 24 months. - The Lower Face V-Lift (The Bio-Structural Protocol)
Specifically designed to combat the jowling and turkey neck common with rapid GLP-1 weight loss.
• The Strategy:
o Hyperdilute Radiesse: Merz Aesthetics’ protocol for 2025 involves thinning Radiesse with saline and lidocaine to act as a pure skin-tightening agent rather than a filler. It is fanned across the jawline and neck.
o Structural Fillers (Juvéderm Volux): Applied only at the chin and jaw angles to provide bone-like support where fat has been lost.
o Neurotoxin: Used in the Nefertiti Lift technique to relax the platysmal bands (neck muscles) that pull the lower face downward. - The Regenerative Trio (Energy + Biologics)
This 2025 protocol focuses on skin contraction and cellular health.
Radiofrequency Microneedling: Deep radiofrequency microneedling to contract the fibroseptal network.
Exosome Therapy: Applied topically or injected immediately after RF to signal young cell behavior and speed up the patient’s healing times.
SKINVIVE by JUVÉDERM: Used as a finishing touch to restore the micro-hydration that GLP-1 users often lose due to systemic dehydration. - Professional Guidance for 2025
• The Weight Stability Rule: Most top-tier providers now require patients to be at a stable weight for 3 to 6 months before performing major volume restoration to avoid overfilling as the face continues to change.
• The Protein Threshold: Many 2025 aesthetic consultations now include a nutritional component, requiring patients to maintain 0.8g–1.2g of protein per kg of body weight to ensure the body has the building blocks to actually produce the collagen the treatments are stimulating.
Impact on Aesthetic Business Models
The GLP-1 patient has changed how clinics operate in 2025. According to a panel from The Aesthetic Meeting in 2025, the following is now true.
• Patient Acquisition: Approximately 63% of GLP-1 patients seeking aesthetic treatments in 2025 are first-time visitors to a medical spa, creating a massive new top-of-funnel patient for the entire industry.
• Spending Shifts: GLP-1 medications and related maintenance now appear in 10% of all body contouring visits, signaling a shift toward internal-external weight management.
• Bundled Wellness: Practices are increasingly pivoting to a Holistic Center model, bundling weight loss programs with hormone replacement therapy (HRT) and traditional aesthetic injectables.
• The Shortage Cliff: In early 2025, the FDA officially removed Tirzepatide (Zepbound) from the shortage list. This effectively ended the widespread era of “compounded” versions, forcing many clinics to transition their patients back to branded or newly approved generic supplies.
Notable 2025 Trends
• Gourmand Fragrance Spike: An unusual side effect—sales of “dessert-themed” perfumes rose 24% in 2025 as GLP-1 users replaced the sensory input of eating sweets with sensory scents, according to the U.S. Chamber of Commerce.
• The Maintenance Challenge: Data from the Cleveland Clinic in June 2025 showed that 50% of patients struggle to stay on GLP-1s long-term due to cost or side effects. This has led aesthetic clinics to focus on bridge programs that help patients maintain their new physique through body contouring and nutrition.
Next Up: Part IV in Christensen Consulting’s 2025 Medical Aesthetic Year in Review, The Dangerous Impact of Problem Practitioners on the Industry.
Read past installments of this report:
Part I: New Indications, Approvals, and Entrants Into the Market
Part II: A Focus on Pumping Up Filler Futures
Leave a Reply